BACKGROUND: Using national data (2001-2003), this study explored the risk of @entity583 ( @entity583 ), @entity951 , @entity64 and @entity4905 ( @entity4905 ) in long-term users of @entity13586 and @entity12698 in Taiwan and compared this data with that for those using @entity9213 . METHODS: @entity1 included in the study had used @entity12698 , @entity13586 or @entity9213 for at least 180 days. Data were taken from National Health Insurance database for the period from 2001 to 2003. Main outcome measurements were the occurrence of @entity583 , @entity951 , @entity64 or @entity4905 after the initiation of long-term continuous use of these drugs. @entity1 -time exposures and hazard ratios (HRs) were calculated based on data from 9602 eligible @entity1 . RESULTS: In @entity1 without a history of a cardiovascular event within the year before drug treatment began, the overall rates of @entity583 , @entity951 , @entity64 and @entity4905 were 1.1%, 0.6%, 2.0% and 0.6%, respectively. In those with cardiovascular events in the year before treatment began, the overall rates of @entity583 , @entity951 , @entity64 and @entity4905 were 5.0%, 4.8%, 6.6% and 5.8%, respectively. Compared with @entity9213 users, @entity12698 users had lower HRs for the development of @entity583 (HR 0.78, 95% CI 0.63, 0.96) and @entity64 (HR 0.81, 95% CI 0.70, 0.93). @entity13586 users were at no higher risk of cardiovascular events than those receiving @entity9213 . Regardless of treatment, having had a cardiovascular event in the year before treatment began played a significant role in the development of the same cardiovascular event during the prescription period; the HRs associated with having had the same cardiovascular event in the past year, versus not having had such an event, were 3.02 (95% CI 1.44, 6.32) for @entity583 , 5.82 (95% CI 3.19, 10.63) for @entity951 , 2.44 (95% CI 1.79, 3.33) for @entity64 and 7.16 (95% CI 3.70, 13.87) for @entity4905 . CONCLUSIONS: @entity1 taking @entity12698 had a lower risk of cardiovascular events than those taking @entity9213 . @entity1 taking @entity13586 were not found to be at higher cardiovascular risk than those taking @entity9213 . The most significant determinant of cardiovascular risk was a history of such @entity65 in the year preceding treatment initiation. @entity1 with a history of other medical conditions also appeared to be at higher risk of adverse cardiovascular events.

Cardiovascular events associated with long-term use of @entity12698 , @entity13586 and XXXX in Taiwan: an observational study.

@entity1 :: ('9606', 'Species') :: ['Person', 'Patients', 'patients'] @entity13586 :: ('MESH:C116926', 'Chemical') :: ['rofecoxib', 'Rofecoxib'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity12698 :: ('MESH:C105934', 'Chemical') :: ['celecoxib'] @entity9213 :: ('MESH:C065757', 'Chemical') :: ['meloxicam'] @entity4905 :: ('MESH:D002546', 'Disease') :: ['transient ischaemic attack', 'TIA'] @entity951 :: ('MESH:D000787', 'Disease') :: ['angina'] @entity583 :: ('MESH:D009203', 'Disease') :: ['AMI', 'acute myocardial infarction'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']
@entity9213 :: (MESH:C065757,Chemical) :: ['meloxicam']
